Mindfulness sleep program to prevent depression in pregnancy and after birth
Tests a mindfulness sleep program for pregnant women with insomnia to prevent depression.
Key facts
- Who runs it
- Henry Ford Health System
- Where
- Novi, United StatesSee the site
- Trial code
- Registry title
- Sleep to Reduce Incident Depression Effectively in Peripartum
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 500 people, planned
- Started
- 10 Dec 2024
- Expected to end
- 29 Feb 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)
- Treatment-as-usual (TAU)
- Record updated
- 17 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women with insomnia (trouble sleeping) who do not have major depression. It tests an online sleep program to help prevent depression during and after pregnancy.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Pregnant with one baby, week 14-31 of pregnancy at screening. Insomnia disorder lasting ≥1 month, Insomnia Severity Index (ISI) score ≥ 11. Edinburgh Postnatal Depression Scale score <13 and no current major depression.
- Earlier treatment
- Not currently in therapy for major depression or insomnia disorder.
Main reasons for not taking part
- High-risk pregnancy, such as pre-eclampsia or placenta previa with bleeding (high blood pressure and diabetes are allowed)
- Active intent to end one's life
- Night or rotating shift work, or planned travel across 3 or more time zones in the 2 months after screening
- Untreated restless legs syndrome (RLS), or strong daytime sleepiness (Epworth Sleepiness Scale >15)
- Uncontrolled sleep or mental disorder, such as narcolepsy, bipolar disorder or epilepsy
This trial only enrols pregnant participants. The registry sentence this rests on: 1. Singleton pregnancy, gestational week 14-31 at screening.
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Singleton pregnancy, gestational week 14-31 at screening
- DSM-5 Insomnia Disorder (≥1 month duration)
- Insomnia Severity Index (ISI) score ≥ 11
- Edinburgh Postnatal Depression Scale score<13 at screening
- No current DSM-5 Major Depression
- Reliable internet access for treatment and assessments
- Not currently engaged in therapy for major depression or insomnia disorder
- Age 18 years or older
Who cannot take part
- High risk pregnancy (pre-eclampsia, placenta previa w/ hemorrhage, other conditions deemed serious risk to mother or fetus; hypertension and diabetes are allowed)
- Uncontrolled sleep or mental disorder inappropriate or unsafe for sleep restriction (narcolepsy, bipolar, epilepsy, etc.)
- Active suicidal intent
- Night or rotating shift work, anticipated travel across time 3 or more time zones in the 2 months after baseline screening
- Untreated RLS (treated RLS is OK)
- Excessive daytime sleepiness; Epworth Sleepiness Scale>15
Where in United States
- Henry Ford Medical CenterNovi, United StatesContact: David Kalmbach, PhDTaking people
About the trial
What the trial wants to find out
Perinatal depression (PND) is the most common complication in pregnancy and postpartum, which increases risk for adverse perinatal outcomes such as preterm birth, maternal suicidal thoughts, and impaired mother-infant bonding. Insomnia often precedes PND cases and may serve as an entry point for interventions preventing PND. The proposed project is a large-scale clinical trial to test the effectiveness of a mindfulness-based sleep program designed for pregnant women to improve sleep and alleviate cognitive arousal to reduce risk for PND across pregnancy and postpartum.
The 2 groups in the trial
- Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)Treatment being tested
PUMAS is a clinician-administered psychotherapy intervention for prenatal insomnia that includes six weekly 60-minute sessions in an individual format. PUMAS combines behavioral sleep strategies with mindfulness exercises and tailors all components to pregnancy to improve sleep quality. PUMAS will be delivered via telemedicine video.
- Treatment-as-usual (TAU)Existing treatment, for comparison
TAU reflects real-world care where patients and their providers make their own treatment decisions for treating prenatal insomnia. Common TAU options include over-the-counter sleep aids, sleep hygiene education, melatonin, and cognitive-behavioral therapy for insomnia. The TAU group will be well-characterized (i.e., the investigators will monitor interventions administered by the usual care providers and collect information on dosage, frequency, duration, adherence) to best describe treatment options sought and completed in the real world.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Sleep to Reduce Incident Depression Effectively in Peripartum
- Plain-language title
- Mindfulness sleep program to prevent depression in pregnancy and after birthGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 17 April 2026